skip to Main Content

dr. Sylvia Snauwaert

Gebruik de knoppen om de artikels, publicaties en presentaties van deze auteur te raadplegen.

Geen resultaten gevonden

Guidelines of the Belgian Hematology Society on the use of stem cell transplantation in lymphoproliferative diseases.

Belgian journal of hematology volume 10 issue 2 march 2019 p 69-79.

Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study.

Br J Haematol. 2019 Nov 8. doi: 10.1111/bjh.16300. PMID: 31702836

TARP is an immunotherapeutic target in acute myeloid leukemia expressed in the leukemic stem cell compartment.

Haematologica. 2019 Aug 1. pii: haematol.2019.222612. doi: 10.3324/haematol.2019.222612. PMID: 31371409

Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.

Lancet Haematol. 2019 Aug;6(8):e429-e437. doi: 10.1016/S2352-3026(19)30089-4. Epub 2019 Jul 8. PMID: 31296423

Highlights in lymphoma.

Belgian Journal of Hematology. 2018 Feb; 9(1): 14-18.

Hodgkin’s lymphoma: Belgian Hematology Society guidelines in diagnosis, treatment and follow-up.

Belgian Journal of Hematology. 2018; 9; 214-224.

Clinical Outcomes with Single-Agent ibrutinib for relapsed/refractory mantle cell lymphoma: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

Effectiveness and safety of Ibrutinib for Chronic Lymphocytic Leukemia in Routine Clinical Practice: IA of the Belgian Ibrutinib Real-World Data (BiRD) Study.

20th Post-ASH Meeting.

12/01/2018
Brussel
Back To Top